Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Platform Trial of Vilobelimab in ARDS
NCT06701682Phase 2Recruiting
- Sponsor
- PPD
- Start
- Jun 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vilobelimab in acute respiratory distress syndrome (ARDS), sponsored by PPD. Started Jun 2025; status: recruiting.
02
Drugs
vilobelimab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06701682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701682.